Cisplatin is a member of platinum-containing anti-cancer drugs that causes cross-linking of DNA and ultimately cancer cell apoptosis. The therapeutic function of cisplatin on various types of cancers has been widely reported but the side effects have been discovered together and nephrotoxicity has been regarded as major side effect of cisplatin. To select candidates for new sensitive nephrotoxicity biomarker, we performed proteomic analysis using 2-DE/MALDI-TOF-MS followed by cisplatin treatment in human kidney cell line, HK-2 cells, and compared the results to the gene profi le from microarray composed of genes changed in expression by cisplatin from formerly reported article. Annexin A5 has been selected to be the most potential candidate and it has been identifi ed using Western blot, RT-PCR and cell viability assay whether annexin A5 is available to be a sensitive nephrotoxic biomarker. Treatment with cisplatin on HK-2 cells caused the increase of annexin A5 expression in protein and mRNA levels. Overexpression of annexin A5 blocked HK-2 cell proliferation, indicating correlation between annexin A5 and renal cell toxicity. Taken together, these results suggest the possibility of annexin A5 as a new biomarker for cisplatin-mediated nephrotoxicity.
INTRODUCTION
Cisplatin (cis-diammine-dichloro-platinum II ) is the fi rst member of metal-containing chemotherapeutic drugs and its fi rst clinical treatment was performed for testicular cancer in 1979 (Prestayko et al., 1979) . Since the fi rst clinical trial, cisplatin has been widely used as an intravenously administered anticancer agent that is available to be applied to various types of cancers such as carcinomas of testis, ovary, neck and head. This practical anti-cancer drug binds and interacts with DNA to form adducts, mainly causing intrastrand cross-links (Sherman and Lippard, 1987; Siddik, 2003) . DNA adducts formed by cisplatin activate several signaling pathways that ultimately trigger apoptosis such as those of ATR, p53 and MAPK (Wang et al., 2000; Damia et al., 2001) , which makes cisplatin possible to be used as an anti-cancer drug.
In spite of various abilities of cisplatin as a chemotherapeutic drug, limits in clinical use still exist due to serious side effects such as oto-, myelo-, neuro-and nephrotoxicity (Laurell and Jungnelius, 1990; Harmers et al., 1991; Treskes and van der Vijgh, 1993) . Among them, nephrotoxicity is known as representative dose-limiting side effect of cisplatin that induces promotion of apoptosis and necrosis of renal epithelial cells (Hanigan and Devarajan, 2003) and considerable efforts have been contributed to overcome it. To establish effective way that makes reduction of side effects possible, studies to identify the level or mechanism of nephrotoxicity occurred by cisplatin have been widely investigated.
It has been signifi cantly emphasized that the biomarkers sensitive for nephrotoxicity are essential to detect the level of toxicity and reduce it. For this reason, various types of nephrotoxic biomarkers such as NGAL (neutrophil gelatinase-associated lipocalin) and NAG (N-acetyl-β-D-glucosaminidase) have been discovered and some of them are in clinical use (Devarajan, 2007; Franke et al., 2010) . Despite serious necessity and much effort, widely accepted and sensitive biomarker for nephrotoxicity still has not been discovered yet and it needs to be investigated further.
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Biomol Ther 21(3), 190-195 (2013) www.biomolther.org Annexin A5 has specifi c properties that it requires higher calcium concentration than other types of annexin proteins for phospholipid binding and it forms two-dimensional networks on lipid bi-layers through binding with phosphatidylserine to activate its function (Raynal and Pollard, 1994; Reviakine et al., 2000) . Recently, it also has been identifi ed that this networks are available to open a new portal for cellular entry, which is able to suggest the possibility for contribution of annexin A5 to apoptosis (Kenis et al., 2004) . These properties of annexin A5 make it possible to suggest that annexin A5 may be involved in cisplatin-induced toxicity and could be used as a new biomarker for side effect of cisplatin.
In present study, we performed experiments to fi nd new sensitive biomarker for nephrotoxicity. Screening for selection of candidates, proteomic analysis was performed. Because annexin A5 was selected as one of the most potential candidates, validation of sensitivity of annexin A5 for cisplatininduced nephrotoxicity has also been implemented.
MATERIALS AND METHODS

Reagents
Cisplatin was purchased from Sigma-Aldrich (St. Louis, MO, USA). DMEM medium, penicillin or streptomycin was obtained from Welgene (Daegu, Korea). Fetal bovine serum (FBS) or enhanced chemiluminescence (ECL) detecting reagent was purchased from Thermo Fisher Scientifi c (Rockford, IL, USA). BCA protein assay kit was from Pierce Chemical Co. (Rockford, IL, USA). EZ-CYTOX cell viability kit was purchased from Daeil lab service Co., Ltd (Seoul, Korea). Rabbit polyclonal antibody for annexin A5 was obtained from Sigma-Aldrich (St. Louis, MO, USA). HRP-conjugated goat anti-rabbit IgG was purchased from Santa Cruz Biotechnology (Santa CRUZ, CA, USA). Maloney murine leukemia virus (M-MLV) reverse transcriptase and RNase inhibitor (RNasin) were obtained from Promega (Madison, WI, USA). Ex Taq DNA polymerase was purchased from TaKaRa Bio (Shiga, Japan). Other reagents and chemicals were commercially available of the highest quality.
Cell culture
Immortalized human kidney epithelial cells (HK-2) was obtained from American Type Culture Collection (ATCC, Manassa, VA, USA) and cultured in DMEM medium supplemented with 10% (v/v) heat-inactivated FBS, 100 unit/ml penicillin, and 100 μg/ml streptomycin. Cells were maintained at 37 o C in a humidifi ed atmosphere of 5% CO 2 .
Cell treatment and harvest
Cisplatin was dissolved in sterile 0.9% NaCl solution. Cisplatin solutions were used for no longer than 3 days. Cells were treated with cisplatin and incubated at 37 o C in a humidifi ed atmosphere of 5% CO 2 for the designated time. After incubation, cells were harvested by scrapping and washed with phosphate-buffered saline (PBS). Cells were centrifuged at 1,000xg for 4 min at 4 o C and the pellets were stored in -70 o C.
2DE/MALDI-TOF-MS analysis
For total cell lysates, cells were solubilized with ice-cold 50 mM Tris-HCl (pH 8.0) containing 150 mM NaCl, 1% nonidet P-40, 1 mM PMSF, 1 μg/ml aprotinin, and 1 μg/ml leupeptin (pH 7.4). Extracted proteins (20 μg) were prepared in adequate volumes determined by BCA protein assay reagents and separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on 10% polyacrylamide gels. Seperated proteins were dyed using silver staining. For protein identifi cation by peptide mass fi ngerprinting, protein spots were excised, digested with trypsin (Promega, Madison, WI, USA), mixed with α-cyano-4-hydroxycinnamic acid in 50% acetonitrile/0.1% TFA, and subjected to MALDI-TOF analysis (Ettan MALDI-TOF Pro, Amersham Biosciences, Piscataway, NJ, USA) as described (Fernandez et al., 1998) . Spectra were collected from 350 shots per spectrum over m/z range 600-3,000 and calibrated by two point internal calibration using trypsin auto-digestion peaks (m/z 842.5099, 2211.1046). Peak list was generated using Ettan MALDI-TOF Pro Evaluation Module (version 2.0.16). Threshold used for peak-picking was as follows: 5,000 for minimum resolution of monoisotopic mass, 2.5 for S/N. The search program MASCOT (http://www. matrixscience.com/) was used for protein identifi cation by peptide mass fi ngerprinting. The following parameters were used for the database search: trypsin as the cleaving enzyme, a maximum of one missed cleavage, iodoacetamide (Cys) as a complete modifi cation, oxidation (Met) as a partial modifi cation, monoisotopic masses, and a mass tolerance of ± 0.1 Da. PMF acceptance criteria is probability scoring.
Western blot
Whole cell lysates were prepared and protein concentration was determined using BCA Protein Assay Reagents (Pierce). Cellular extracts (20 μg) were separated on 10% SDS-PAGE at 100 V and transferred onto 0.45 μm PVDF membrane. Nonspecifi c binding was blocked with 5% nonfat milk in tris-buffered saline containing 0.1% tween-20 (TBS-T) for 2 h at 4 o C. Membranes were then incubated for overnight with primary antibody specifi c for annexin A5 at a 1:500 dilution in TBS-T. Horseradish peroxidase (HRP)-conjugated secondary antibody was done at 4 o C for 2 h. Proteins were visualized by an ECL method (Thermo) and the band intensity was analyzed by ChemiDoc XRS densitometer and quantifi ed by Quantity One software (BioRad).
RT-PCR
Total RNA was extracted using Ribospin TM (GeneALL, Seoul, Korea). Total RNA (500 ng) was transcribed at 37 o C for 1 h in a volume of 20 μl containing 5x RT buffer, 10 mM dNTPs, 40 units of RNase inhibitor, 200 units of M-MLV reverse transcriptase, and 100 pmole of oligo-dT primer. Subsequently, 0.8 μl of the reaction mixtures from each sample were amplifi ed with 10 pmole of each oligonucleotide primers, 0.2 mM dNTPs, 1.5 mM MgCl 2 and 1.25 units of Ex Taq DNA polymerase in a fi nal volume of 25 μl. PCR was performed as follows: one cycle of 95 o C for 2 min, followed by 35 cycles of denaturation at 95 o C for 10 s, annealing at 63 o C for 15 s, and extension at 72 o C for 15 s. The number of cycles for amplifi cation was optimized in preliminary experiments to ensure that the PCR has not reached its plateau. PCR products were applied to a 2% (w/v) agarose gel electrophoresis, and analyzed by ChemiDoc XRS (Bio-Rad, Hercules, CA). Human annexin A5 cDNA was amplifi ed using a sense primer (5'-CAGTCTAGGTGCAGCT-GCCG-3') and an antisense primer (5'-GGTGAAGCAGGAC-CAGACTGT-3'). Human GAPDH was amplifi ed using a sense primer (5'-TGAACGGGAAGCTCACTGG-3') and an antisense primer (5'-TCCACCACCCTGTTGCTGTA-3'). 
Statistical analysis
Using one-way analysis of variance, statistical analysis was performed followed by Dunnett's Multiple Comparison t-test using Graph-Pad Prism Software (GraphPad Software Inc., San Diego, CA) when appropriate. The difference was considered statistically signifi cant at p<0.05.
RESULTS
Proteomic analysis for cisplatin-induced nephrotoxicity biomarkers
To fi nd valuable biomarker for cisplatin-induced nephrotoxicity, human kidney epithelial cells (HK-2) were treated with 20 μM of cisplatin for 24 h or 48 h. To identify which proteins showed changes in expression, we performed proteomic analysis by two-dimensional gel electrophoresis (2DE)/MALDI-TOF-MS. As shown in Fig. 1A , considerable amounts of spots that refl ect the expression of proteins were elevated in density when cells were treated with cisplatin for 24 h or 48 h.
Selection of new biomarker candidate for nephrotoxicity
From the results of proteomic analysis, 160 spots showing signifi cant increase of expression were selected as candidates for nephrotoxic biomarkers. To identify whether the HK-2 cells were treated with 20 μM cisplatin for the indicated times (0, 6, 12, 24 or 48 h). After harvesting, total cellular lysates were prepared for Western blot analysis using antibody against annexin A5. GAPDH was used as a loading control. (B) RT-PCR. HK-2 cells were treated with 20 μM cisplatin for conducted times (0, 6, 12, 24 or 48 h). After harvesting, total RNA was isolated and amplifi ed using specifi c primers. The PCR products were separated on 2% agarose gel. Expression of GAPDH mRNA was determined as a RNA control. corresponding results were observed in vivo, we compared proteins each spots represented to the previously reported DNA microarray results (Wang et al., 2008) . In this paper, male rats were intravenously treated with cisplatin for 1, 3 and 5 days. Various types of genes reported to be associated with cisplatin-induced nephrotoxicity were examined and their level of change in expression were profi led. As a result of comparison, several proteins were matched and narrowed for 5 candidates in Table 1 . Annexin A5, one of matched proteins, was selected as the most potential new nephrotoxic biomarker candidate due to signifi cant changes in both studies and its property to accumulate in kidney. Furthermore, it has been recently reported that annexin A5 mediates internalization on cell surface and this phenomenon is activated early after initiation of apoptosis (van den Eijnde et al., 1997; Kenis et al., 2004) . This potential ability of annexin A5 was also considered as proper reason for selection.
Eff ect of cisplatin on annexin A5 expression in HK-2 cells
To identify whether annexin A5 is increased by cisplatin, HK-2 cells were treated with 10, 20, 30 or 40 μM of cisplatin and expression of annexin A5 was investigated using Western blot and RT-PCR. As shown in Fig. 2-3 , expression of annexin A5 was signifi cantly promoted due to cisplatin treatment in time-and concentration-dependent manners. Moreover, to explore the effect of annexin A5 on kidney cells, viability of HK-2 cells was detected after annexin A5 over-expression. Protein level of annexin A5 in HK-2 cells was measured after transfection with pcDNA3. 1zeo-annexin A5 for 24 h. As shown in Fig. 4A , we found that annexin A5 was signifi cantly increased by transfection. Over-expression of annexin A5 inhibited cell proliferation in Fig. 4B . At 48 h, mock-transfected cells showed about 160% of viability but 94% of viability was shown in annexin A5-transfected cells. These results elucidate that annexin A5 may play an important role in cisplatin-induced toxicity in HK-2 cells.
DISCUSSION
Platinum-based anti-neoplastic agents have been widely used as anti-cancer drugs. Among them, cisplatin, a member of fi rst generation of this group, is applied to various types of tumors including ovarian, lung, head and neck, bladder and less severe breast and gastric cancer (Lokich and Anderson, 1998) . Despite usefulness of cisplatin, the treatment of this agent is limited due to serious side effects including nephrotoxicity (Donzelli et al., 2004) . The most signifi cant mechanism underlying cisplatin-induced nephrotoxicity is reported to be apoptosis (Hanigan and Devarajan, 2003) . Considerable efforts have been made for decades to eliminate the toxicity of cisplatin and several ways were identifi ed that are available to reduce cisplatin-induced nephrotoxicity such as pre-hydration of patients and dual use of diuretics (Quasthoff and Hartung, 2002) . However, nephrotoxicity still remains as the major dose-limiting side effect of cisplatin and the mechanism or solution for cisplatin-induced nephrotoxicity has not been yet clarifi ed. For these reasons, the investigations to develop the ways for reduction of nephrotoxicity have to be more implemented.
Annexins are proteins that bind to cellular membranes containing phospholipids with negative charge in Ca 2+ -dependent manner (Markoff and Gerke, 2005) . These proteins are expressed in various types of animals and plants and classifi ed into 5 groups, A, B, C, D, and E (Moss and Morgan, 2004) . Twelve types of annexins have been identifi ed in human with tissue-and cell type-specifi c expressions (Markoff and Gerke, 2005) . Among them, annexin A1, A2, A3 and A5 are expressed HK-2 cells were treated with designated concentrations of cisplatin for 24 h. After harvesting, total cellular lysates were prepared for Western blot analysis using antibody against annexin A5. GAPDH or β-actin was used as a loading control. (B) RT-PCR. HK-2 cells were treated with conducted concentrations of cisplatin for 24 h. After harvesting, total RNA was isolated and amplifi ed using specifi c primers. The PCR products were separated on 2% agarose gel. Expression of GAPDH mRNA was determined as a RNA control. in digestive or ductal organs, especially in kidney (Pepinsky et al., 1988; Dreier et al., 1998) .
Annexin A5, a member of annexin protein family, is basically known as Ca 2+ and negatively charged phospholipid binding protein and widely used as a detector for apoptosis due to ability of binding to phosphatidylserine exposed to outside of cells during apoptosis (Vermes et al., 1995) . Recently, it has been reported that annexin A5 forms two-dimensional network covering phosphatidylserine-expressed cell surface through trimerization using intramolecular salt bridges (Kenis et al., 2004; Ungethum et al., 2011) . The network formed by annexin A5 induces bending of cell membrane and subsequent formation of endocytic vesicle, which makes a new portal for cell entry open (Kenis et al., 2004; Kenis et al., 2007) . This endocytic pathway induced by annexin A5 was observed to be activated early after initiation of apoptosis along with appearance of phosphatidylserine molecules on cell surface and reported not to operate commonly in healthy tissues (van den Eijnde et al., 1997; Kenis et al., 2004) . Although the contribution of annexin A5 on apoptosis is unclear, these properties of annexin A5 make it possible that annexin A5 has potential to participate in apoptosis and this potential ability of annexin A5 may play an important role in kidney malfunction due to accumulation of annexin A5 in kidney.
In this study, we explored a new biomarker for cisplatin-induced nephrotoxicity. To select proteins that show changes in expression followed by cisplatin treatment, proteomic analysis using 2DE/MALDI-TOF-MS was applied. The proteins altered in expression level were compared to the profi le of genes that changed in expression due to cisplatin treatment in vivo model (Wang et al., 2008) . As outcome of comparison between proteomic results and genomic DNA microarray results, we found that annexin A5 was increased in both studies. Due to one of the properties of annexin A5 that it is accumulated in kidney (Markoff and Gerke, 2005) , we selected annexin A5 as one of the potential candidates in proteins obtained from the results. To evaluate whether annexin A5 is able to refl ect nephrotoxicity sensitively, we performed Western blot and RT-PCR on expression of annexin A5 in HK-2 cells and it has been resulted in increase of annexin A5 expression followed by cisplatin treatment in both protein and mRNA levels. Direct evidence for correlation between annexin A5 expression and cytotoxicity was obtained by measuring cell viability. According to our results, over-expression of annexin A5 signifi cantly inhibited proliferation of HK-2 cells. Recently, it has been reported that over-expression of annexin A5 increases apoptosis elicited by basic calcium phosphate crystals in articular chondrocyte (Ea et al., 2008) . Although the mechanism has not been yet identifi ed, we suggest that annexin A5 may play an important role in apoptosis.
In summary, our study suggests annexin A5 as a new sensitive biomarker for cisplatin-induced nephrotoxicity. Based on the report that cisplatin-induced nephrotoxicity is elicited by various pathways (Yao et al., 2007) , annexin A5 has possibility to be a general biomarker for nephrotoxicity obtained from various types of kidney malfunction. Formerly, it has been reported that increase of excreted annexin A5 in urine of patients with acute renal impairments is available to detect using ELISA (Matsuda et al., 2000) . This report and our study could suggest that annexin A5 may be useful as clinical biomarker of cisplatin-induced nephrotoxicity. Although in vivo biomarkers are more useful in clinical aspects, fi nding in vitro biomarkers is also important to explore basic molecular mechanism of nephrotoxicity and predict more precisely and rapidly in vivo toxicity. Based on the ability of annexin A5 inducing endocytic pathway, we suggest that the potential role of annexin A5 in apoptosis may be related to pro-apoptotic pathways with pore formation. Recently, it has been reported that annexin A4 is up-regulated by cisplatin and over-expression of annexin A4 decreases cell viability (Yamashita et al., 2012) . Due to the common property of annexin A4 and A5 that both annexins are more closely related to ion channel regulation than other annexins, the effects of cisplatin-induced annexin A4 and A5 on cell viability may be linked with their ability as regulator of ion channels. Further studies need to be conducted to identify the exact mechanism exploring the contribution of annexin A5 to renal cell apoptosis and whether annexin A5 could be used as general biomarker for wide range of renal failure.
